This biotechnology company develops immunotherapies based on galectin modulation for treating cancer, autoimmune diseases, and chronic inflammatory conditions. The core strategy involves designing innovative therapeutic approaches derived from scientific discoveries concerning galectins and their glycosylated ligands. The company aims to transform these glycocience findings into novel drug candidates to address unmet medical needs in these serious diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer, autoimmune diseases, and chronic inflammatory conditions present significant therapeutic challenges. Current treatment options often fail to precisely modulate immune responses, leading to suboptimal patient outcomes and reduced quality of life.
Solution
This startup is developing a novel class of immunotherapies based on the modulation of galectins, key regulators of the immune system. By targeting galectins with monoclonal antibodies, the company aims to restore immune homeostasis and enhance the body's natural ability to fight disease. Their approach leverages nearly 30 years of research into the role of galectins and their glycosylated ligands in immune regulation. The resulting therapies are designed to offer a more targeted and effective approach to treating cancer, autoimmune disorders, and chronic inflammation.
Target Audience
The primary target audience includes patients suffering from cancer, autoimmune diseases, and chronic inflammatory conditions, as well as pharmaceutical companies seeking innovative immunotherapeutic agents.
Features
- Monoclonal antibodies targeting specific galectin proteins
- Modulation of "Glycocheckpoints" to fine-tune immune responses
- Therapeutic strategies for cancer, autoimmune diseases, and chronic inflammatory conditions
- Preclinical studies validating the efficacy and safety of galectin-modulating antibodies
- Intellectual property portfolio including patents related to galectin-based therapies